Breast Cancer Drugs Show Promise for Rare Bile Duct Cancer

A new trial reveals potential benefits of HER2-targeting drugs for bile duct cancer patients.

The phase two trial involved 217 patients with different tumors showing HER2 changes.
Tucatinib and trastuzumab, drugs targeting HER2, were administered in 21-day cycles.
Overall, 22.2% of patients experienced tumor shrinkage, with 46.7% response in bile duct cancer cases.
The chemotherapy-free treatment was well-tolerated with minimal side effects reported.
Findings will be presented at the EORTC-NCI-AACR Symposium, highlighting the need for further research.